ReviewCurrent oncology reports2026
Diffusion Models in Oncology: a Review of Current Applications.
Review in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewDiffusion models are an emerging class of generative artificial intelligence with increasing relevance in oncology. This review examines how diffusion-based methods are being applied across cancer imaging, radiotherapy, and therapeutic development, and discusses their translational potential and key barriers to clinical adoption. RECENT
findingsRecent studies demonstrate that diffusion models can generate high-quality synthetic medical images across multiple modalities, improving diagnostic model performance, particularly for rare tumor subtypes. Diffusion-based approaches have shown superior performance in tumor and tissue segmentation, radiotherapy dose prediction, and synthetic CT generation from cone-beam CT for adaptive treatment planning. Beyond imaging, diffusion models have enabled the design of novel small molecules and antibodies, such as those targeting the HER2 antigen, with experimentally validated anticancer activity. However, challenges remain, including high computational demands, inference latency, privacy risks related to data memorization, and limited validation in real-world clinical workflows. Diffusion models are emerging as a versatile generative framework with measurable impact across multiple domains of oncology. Continued progress in efficiency, validation, and integration will be essential for translating these methods from research settings into routine clinical care.
Indexed as
Identifiers
41912923What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.